More recently, another MEK inhibitor, cobimetinib—when used in combination with the BRAF-inhibitor, vemurafenib—was reported to improve progression-free survival among patients with BRAF V600-mutated metastatic melanoma [25]. Here, BRAF is linked to metastatic melanoma.